Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 2, 2026, details the execution of a previously announced special dividend and the filing of the Certificate of Designation for Series O Convertible Preferred Stock. The report covers events occurring on the Record Date of March 2, 2026, with the dividend expected to be paid by March 4, 2026.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the capital structure adjustment:
- Dividend Declaration: One-tenth (0.1) of one share of Series O Preferred Stock for each share of Common Stock and Eligible Warrants outstanding.
- Shares Designated: 1,557,000 shares of Series O Convertible Preferred Stock.
- Stated Value: $8.01 per share of Series O Preferred Stock.
- Liquidation Preference: $0.0001 per share (par value), with specific provisions for Chapter 7 bankruptcy scenarios.
- Dividends: Holders of Series O Preferred Stock are not entitled to receive dividends.
Material Changes
The material change reported is the formal creation and issuance of the Series O Preferred Stock via a special dividend. This alters the company's equity structure by introducing a new class of convertible preferred stock with specific liquidation and conversion rights, distinct from the existing Common Stock.
Outlook, Management Commentary, and Risks
Conversion Mechanics:
- Optional Conversion: The Company may elect to convert all Series O shares to Common Stock at any time prior to December 31, 2026.
- Automatic Conversion: If not converted earlier, all shares will automatically convert on December 31, 2026.
- Conversion Price: Based on the "Minimum Price," defined as the lower of the closing price immediately preceding the conversion date or the average closing price of the five trading days preceding that date.
- Ownership Cap: Conversion is subject to a "Maximum Percentage" limitation, preventing any holder from beneficially owning more than 19.99% of the outstanding Common Stock. Excess shares may be issued as Pre-Funded Warrants exercisable at $0.001 per share.
- Transferability: Series O Preferred Stock cannot be transferred, assigned, or pledged without prior written consent from the Company.
- Liquidity: There is no established trading market for the Series O Preferred Stock, and the Company does not intend to list it on any exchange.
- Voting Rights: The Series O Preferred Stock generally has no voting rights, except in specific matters where holders are entitled to one vote per one-tenth of a share.
Key Facts for Investor Verification
- Verify the total number of Common Stock and Eligible Warrants outstanding as of the March 2, 2026 Record Date to confirm the 1,557,000 Series O shares issued.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for detailed definitions of "Deemed Liquidation Event" and specific conversion formulas.
- Monitor the Company's stock price leading up to December 31, 2026, as the "Minimum Price" mechanism will determine the conversion ratio and potential dilution.
- Confirm whether the Company exercises its right to Optional Conversion before the Automatic Conversion Date.
- Check for any subsequent filings regarding the issuance of Pre-Funded Warrants if the 19.99% ownership cap is triggered during conversion.